Adenoid cystic carcinoma of the head and neck – treatment strategies of a highly malignant tumor with variable localizations

Dudde, Florian; Henkel, Kai-Olaf; Barbarewicz, Filip

doi:10.18632/oncoscience.581

Cited by 1 publication

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common initial treatment for ACC is surgery, either with or without radiation therapy [ 2 , 8 ]; nevertheless, most patients later develop metastases or tumor recurrences [ 8 ]. Currently, there is no standard chemotherapy for ACC due to its rarity and unclear molecular etiology, and many patients experience tumor recurrence and metastatic illness [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…ACC exhibits a peak incidence between the sixth and seventh decades of life and is more common in women than men, as evidenced by a reported female-to-male ratio of 3:2 [ 1 ]. Surgery and adjuvant radiotherapy are the preferred treatment modalities for ACC [ 2 ]. However, these treatment modalities are associated with substantial morbidity and a high risk of recurrence and metastatic disease [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Response of FGFR-2 Positive Adenoid Cystic Carcinoma to Futibatinib: A Case Report

Rodriguez,

Shahid,

Badillo

et al. 2024

Cureus

View full text Add to dashboard Cite

Adenoid cystic carcinoma (ACC) is an uncommon and aggressive head and neck cancer mainly affecting minor salivary glands. It affects more women than men in their 60s and 70s. The tumor is typically locally aggressive and has a high rate of distant metastatic disease. This report unveils a potential avenue for targeted therapy for the management of metastatic disease: a patient with ACC who harbored a specific fibroblast growth factor receptor 2 (FGFR-2) mutation and responded significantly to a novel FGFR-2 inhibitor. This finding could pave the way for personalized treatment options for ACC patients with similar genetic alterations. Nevertheless, the use of futibatinib requires further investigation to optimize treatment protocols, including exploring combination therapies, identifying predictive biomarkers for treatment response, and developing strategies to overcome potential resistance.

show abstract

Section: Discussionmentioning

confidence: 99%